Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1963 2
1969 1
1971 1
1972 1
1974 4
1975 1
1976 2
1977 2
1978 2
1980 1
1981 1
1982 1
1983 2
1984 4
1985 3
1986 5
1987 1
1988 1
1989 2
1990 4
1991 2
1992 3
1993 4
1994 4
1995 4
1996 5
1997 1
1998 4
1999 8
2000 10
2001 11
2002 6
2003 11
2004 9
2005 19
2006 14
2007 21
2008 16
2009 22
2010 16
2011 20
2012 25
2013 38
2014 60
2015 102
2016 110
2017 117
2018 149
2019 96
2020 48
Text availability
Article attribute
Article type
Publication date

Search Results

922 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Mawadh
Page 1
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Gökbuget N, et al. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Blood. 2018. PMID: 29358182 Free PMC article. Clinical Trial.
In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10(-3)) received blinatumomab 15 µg/m(2) per day by continuous IV infusion for up to 4 cycles. ...
In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10(-3)) received blinatu …
Prevention of Dislocation After Total Hip Arthroplasty.
Rowan FE, Benjamin B, Pietrak JR, Haddad FS. Rowan FE, et al. J Arthroplasty. 2018 May;33(5):1316-1324. doi: 10.1016/j.arth.2018.01.047. Epub 2018 Mar 7. J Arthroplasty. 2018. PMID: 29525344 Review.
RESULTS: Extremes of age, body mass index >30 kg/m(2), lumbosacral pathology, surgeon experience, and femoral head size influence dislocation rates after THA. ...
RESULTS: Extremes of age, body mass index >30 kg/m(2), lumbosacral pathology, surgeon experience, and femoral head size influence …
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Chow LQM, et al. J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27646946 Free PMC article. Clinical Trial.
Patients and Methods Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pembrolizumab 200 mg intravenously once every 3 weeks. ...Results Of 132 patients enrolled, median age was 60 years (range, 25 to 84 years), 83% were male, and 57% …
Patients and Methods Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pembrolizumab 200 mg int …
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Harrington KJ, et al. Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23. Lancet Oncol. 2017. PMID: 28651929 Free PMC article. Clinical Trial.
Patients were randomly assigned (2:1) to nivolumab 3 mg/kg every 2 weeks (n=240) or investigator's choice (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuximab (250 mg/m(2) after a loading dose of 400 mg/m
Patients were randomly assigned (2:1) to nivolumab 3 mg/kg every 2 weeks (n=240) or investigator's choice (n=121) of methotrexate (40-60 mg/ …
Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults.
Arabi YM, Aldawood AS, Haddad SH, Al-Dorzi HM, Tamim HM, Jones G, Mehta S, McIntyre L, Solaiman O, Sakkijha MH, Sadat M, Afesh L; PermiT Trial Group. Arabi YM, et al. N Engl J Med. 2015 Jun 18;372(25):2398-408. doi: 10.1056/NEJMoa1502826. Epub 2015 May 20. N Engl J Med. 2015. PMID: 25992505 Free article. Clinical Trial.
High-altitude adaptation in humans: from genomics to integrative physiology.
Azad P, Stobdan T, Zhou D, Hartley I, Akbari A, Bafna V, Haddad GG. Azad P, et al. J Mol Med (Berl). 2017 Dec;95(12):1269-1282. doi: 10.1007/s00109-017-1584-7. Epub 2017 Sep 26. J Mol Med (Berl). 2017. PMID: 28951950 Review.
It is estimated that there are around 83 million people who live at altitudes > 2500 m worldwide and are at risk for CMS. In this review, we focus on a human "experiment in nature" in various high-altitude locations in the world-namely, Andean, Tibetan, and Ethiopian po …
It is estimated that there are around 83 million people who live at altitudes > 2500 m worldwide and are at risk for CMS. In this …
Global Alignment and Proportion (GAP) Score: Development and Validation of a New Method of Analyzing Spinopelvic Alignment to Predict Mechanical Complications After Adult Spinal Deformity Surgery.
Yilgor C, Sogunmez N, Boissiere L, Yavuz Y, Obeid I, Kleinstück F, Pérez-Grueso FJS, Acaroglu E, Haddad S, Mannion AF, Pellise F, Alanay A; European Spine Study Group (ESSG). Yilgor C, et al. J Bone Joint Surg Am. 2017 Oct 4;99(19):1661-1672. doi: 10.2106/JBJS.16.01594. J Bone Joint Surg Am. 2017. PMID: 28976431
Multi-institutional, prospective, observational study comparing the Gastrografin challenge versus standard treatment in adhesive small bowel obstruction.
Zielinski MD, Haddad NN, Cullinane DC, Inaba K, Yeh DD, Wydo S, Turay D, Pakula A, Duane TM, Watras J, Widom KA, Cull J, Rodriguez CJ, Toschlog EA, Sams VG, Hazelton JP, Graybill JC, Skinner R, Yune JM; EAST SBO Workgroup: Martin D. Zielinski, MD; Nadeem N. Haddad, MD; Asad J. Choudhry, MBBS; Daniel C. Cullinane, MD; Kenji Inaba, MD; Agustin Escalante; D. Dante Yeh, MD; Salina Wydo, MD; David Turay, MD; Andrea Pakula, MD; Therese M. Duane, MD; Jill Watras, MD; Kenneth A. Widom, MD; John Cull, MD; Carlos J. Rodriguez, DO; Eric A. Toschlog, MD; Valerie G. Sams, MD; Joshua P. Hazelton, DO; John Christopher Graybill, MD, Ruby Skinner, MD, Ji-Ming Yune, MD. Zielinski MD, et al. J Trauma Acute Care Surg. 2017 Jul;83(1):47-54. doi: 10.1097/TA.0000000000001499. J Trauma Acute Care Surg. 2017. PMID: 28422909 Clinical Trial.
922 results
Jump to page
Feedback